ROIV · Roivant Sciences Ltd.

NasdaqHealthcareBiotechnology

Roivant Sciences Ltd Is A Commercial-Stage Biopharmaceutical Company Dedicated To Improving The Delivery Of Healthcare To Patients. It Also Incubates Discovery-Stage Companies And Health Technology Startups Complementary To Its Biopharmaceutical Business. Its Drug Candidate Vtama (Tapinarof) Is A Treatment Of Plaque Psoriasis In Adult Patients And Is In Its Commercial Stage. The Other Drug Candidates In Their Different Stages Of Development Are; Batoclimab, Imvt-1402, Brepocitinib, Namilumab, And Others.

HealthcareNasdaqGB

$46.09

+31.4% latest move

Price & move as of the most recent catalyst (Sep 8) — not a live quote.

FLOAT

502.5M

FREE FLOAT %

70%

SHARES O/S

722.3M

MARKET CAP

$24.99B

EXCHANGE

Nasdaq

COUNTRY

ROIV Catalyst History

Regulatory and ClinicalPrimary Endpoint MetSep 8, 2026 · 6:03am ET

ROIVRoivant Sciences Ltd.

Roivant Sciences Ltd. Announces Positive Phase 2 PHocus Trial Results for Mosliciguat in PH-ILD

Roivant Sciences Ltd. and Pulmovant, Inc. announced the results on September 8, 2026.

Be early on the next ROIV spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →